Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Contrast Agents' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Contrast Agents' found in 17 terms [] and 106 definitions []
previous     36 - 40 (of 123)     next
Result Pages : [1 2 3 4]  [5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
News  (49)  Resources  (7)  Forum  (8)  
 
Cardiovascular ImagingMRI Resource Directory:
 - Cardiovascular Imaging -
 
Cardiovascular MR imaging includes the complete anatomical display of the heart with CINE imaging of all phases of the heartbeat. Ultrafast techniques make breath hold three-dimensional coverage of the heart in different cardiac axes feasible. Cardiac MRI provides reliable anatomical and functional assessment of the heart and evaluation of myocardial viability and coronary artery disease by a noninvasive diagnostic imaging technique.
Cardiovascular MRI offers potential advantages over radioisotopic techniques because it provides superior spatial resolution, does not use ionizing radiation, has no imaging orientations constraints and contrast resolution better than echocardiography. It also offers direct visualization and characterization of atherosclerotic plaques and diseased vessel walls and surrounding tissues in cardiovascular research.
MRI perfusion approaches measure the alteration of regional myocardial magnetic properties after the intravenous injection of contrast agents and assess the extent of injury after a myocardial infarction and the presence of myocardial viability with a technique based on late enhancement. Extracellular MRI contrast agents, like Gd-DTPA, accumulate only in irreversibly damaged myocardium after a time period of at least 10 minutes.
This type of patients may also have an implanted cardiac stent, bypass or a cardiac pacemaker and special caution should be observed on the MRI safety and the contraindications. While a number of coronary stents have been tested and reported to be MRI compatible, coronary stents must be assessed on an individual basis, with the medical team weighing the risks and benefits of the MRI procedure.
Cardiac MRI overview:
Coronary angiography,
Coronary Angiography with D-Tagging
Myocardial perfusion imaging and viability
Calculation of ventricular volume, myocardial mass and wall thickness
Functional parameters
Description of a stenosis or aneurysma
Anatomical display of the heart, vessels and the surrounding tissue
Cardiovascular MRI has become one of the most effective noninvasive imaging techniques for almost all groups of heart and vascular disease.

 
Images, Movies, Sliders:
 Angulation of Cardiac Planes Cine Images of Septal Infarct  Open this link in a new window
      

Courtesy of  Robert R. Edelman

 Left Circumflex Ischemia First-pass Contrast Enhancement  Open this link in a new window
      

Courtesy of  Robert R. Edelman

 Delayed Myocardial Contrast Enhancement from Infarct  Open this link in a new window
 
spacer

• View the NEWS results for 'Cardiovascular Imaging' (6).Open this link in a new window.
 
Further Reading:
  Basics:
Cardiac MRI - Technical Aspects Primer
Wednesday, 7 August 2002
Coronary Artery Disease: Combined Stress MR Imaging Protocol-One-Stop Evaluation of Myocardial Perfusion and Function1
   by radiology.rsnajnls.org    
A Guide To Cardiac Imaging
   by www.simplyphysics.com    
  News & More:
New Imaging Technique Reveals Different Heart Motions by Age, Gender
Thursday, 10 December 2009   by www.sciencedaily.com    
Rockland Technimed: Tissue Viability Imaging
Saturday, 15 December 2007   by www.onemedplace.com    
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
Radiology  (46) Open this link in a new windowUltrasound  (75) Open this link in a new window
Chromium Labeled Red Blood CellsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(Cr(III)-labeled RBC's) Chromium labeled red blood cells have paramagnetic properties and potential as an intravascular MRI contrast agent. The labeling with chromium decreases the relaxation times of packed red blood cells (RBCs). The use of RBCs in nuclear medicine suggests a low toxicity.
See also Contrast Agents, Intravascular Contrast Agents, Blood Pool Agents.

spacer

• View the DATABASE results for 'Chromium Labeled Red Blood Cells' (2).Open this link in a new window

 
Further Reading:
  Basics:
Chromium labeled red blood cells
   by radiopaedia.org    
Artifical Blood
   by medind.nic.in    
MRI Resources 
Intraoperative MRI - Mobile MRI Rental - Implant and Prosthesis pool - Breast MRI - General - Jobs pool
 
Code 7228InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Code 7228, generic name: Ferumoxytol, central moiety: Fe
Code 7228 is the code name for a substance in the development pipeline (AMAG Pharmaceuticals, Inc.) for use as a contrast agent in magnetic resonance angiography (MRA). Ferumoxytol, as a true blood pool agent, resides in the vascular space for an extended period of time and does not leak out into adjacent tissues like currently used gadolinium-based contrast agents. The product is being evaluated in MRA applications for the detection of blood flow in the heart muscle, in exploratory studies for the diagnosis of vulnerable plaque and as a next generation lymph node agent.
Code 7228 is currently in approval phase for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoetin.
It is presently contemplated that Ferumoxytol will compete with the contrast agents Vasovist™ from EPIX Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham.

spacer

• View the DATABASE results for 'Code 7228' (4).Open this link in a new window

 
Further Reading:
  Basics:
Ferumoxytol
   by www.amagpharma.com    
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
News  (49)  Resources  (7)  Forum  (8)  
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mosm/kgH2O
CONCENTRATION 0.5 mol/L
DOSAGE 0.1 mmol/kg / 0.2mL/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Guerbet to Exhibit Recently U.S. Approved Imaging Agents at 100 Year Anniversary of RSNA
Thursday, 13 November 2014   by money.cnn.com    
Searchterm 'Contrast Agents' was also found in the following services: 
spacer
Radiology  (46) Open this link in a new windowUltrasound  (75) Open this link in a new window
Eovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Eovist® (other brand name Primovist™) is a organ specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans. Excretion of Gd-EOB-DTPA in the bile may also permit visualization of both the gall bladder and the bile ducts.
Eovist® brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic and accumulation phase imaging can also be performed after bolus injection of Eovist®. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma at 10 to 20 minutes after injection. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.
WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Drug Development and Approval Process USA, Contrast Medium, Hepatobiliary Contrast Agents, Tumor Specific Agents and Molecular Imaging.


Drug Information and Specification
NAME OF COMPOUND Gadoxetic acid disodium, Gd-EOB-DTPA
DEVELOPER Bayer Schering Pharma AG
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY Short T1-relaxation time
PHARMACOKINETIC 50% hepatobiliary, 50% renal excretion
OSMOLALITY 884 mosm/kgH2O
CONCENTRATION 0.25 mol/L
DOSAGE 12,5 - 25 µmol/kg
PREPARATION Finished product
INDICATION Liver lesions
DEVELOPMENT STAGE for sale
DISTRIBUTOR See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada Eovist® for sale Bayer HealthCare Pharmaceuticals
EU Primovist™ for sale Bayer Schering Pharma AG

spacer

• View the DATABASE results for 'Eovist®' (4).Open this link in a new window

 
Further Reading:
  Basics:
HIGHLIGHTS OF PRESCRIBING INFORMATION
2008   by berlex.bayerhealthcare.com    
MRI Resources 
Image Quality - Chemistry - Veterinary MRI - Contrast Agents - Artifacts - Raman Spectroscopy
 
previous      36 - 40 (of 123)     next
Result Pages : [1 2 3 4]  [5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 20 January 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]